NCT01847573View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-100 in Duchenne Muscular Dystrophy

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

March 30, 2016

Study Completion Date

March 30, 2016

Conditions
Duchenne Muscular Dystrophy
Interventions
DRUG

HT-100

May be administered in either fed or fasted state

Trial Locations (5)

21205

Kennedy Krieger Institute, Johns Hopkins School of Medicine, Baltimore

43205

Nationwide Children's Hospital, Columbus

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

63110

Washington University School of Medicine, St Louis

95817

University of California, Davis Medical Center, Sacramento

Sponsors
All Listed Sponsors
lead

Processa Pharmaceuticals

INDUSTRY

NCT01847573 - Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-100 in Duchenne Muscular Dystrophy | Biotech Hunter | Biotech Hunter